Mechanisms of ligand specificity of the mineralocorticoid receptor

Journal of Endocrinology

Volumn 213, Issue 1, 2012, Pages 15-24

  Fuller, Peter J ^a   Yao, Yizou ^a   Yang, Jun ^a   Young, Morag J ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; CARBOXY TERMINAL TELOPEPTIDE; DEOXYCORTICOSTERONE; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR; LIGAND;

AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL (TOPIC); EPITHELIUM; HUMAN; HYPERKALEMIA; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; ZEBRA FISH; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; METABOLISM;

ALDOSTERONE; ANIMALS; HUMANS; HYDROCORTISONE; LIGANDS; RECEPTORS, MINERALOCORTICOID;

EID: 84860806217     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-11-0372     Document Type: Review

References (86)

1. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE & Evans RM 1987 Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237 268-275.
2. Benhamou B, Garcia T, Lerouge T, Vergezac A, Gofflo D, Bigogne C, Chambon P & Gronemeyer H 1992 A single amino acid that determines the sensitivity of progesterone receptors to RU486. Science 255 206-209.
3. Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ, McKee DD, Consler TG, Parks DJ, Stewart EL, Willson TM et al. 2002 Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110 93-105.
4. Bledsoe RK, Madauss KP, Holt JA, Apolito CJ, Lambert MH, Pearce KH, Stanley TB, Stewart EL, Trump RP, Willson TM et al. 2005 A ligandmediated hydrogen bond network required for the activation of the mineralocorticoid receptor. Journal of Biological Chemistry 280 31283-31293.
5. Bulynko YA & O'Malley BW 2011 Nuclear receptor coactivators: structural and functional biochemistry. Biochemistry 50 313-328.
6. Caprio M, Feve B, Claes A, Viengchareun S, Lombes M& Zennaro MC 2007 Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB Journal 21 2185-2194.
7. De Bosscher K, Haegeman G & Elewaut D 2010 Targeting inflammation using selective glucocorticoid receptor modulators. Current Opinion on Pharmacology 10 497-504.
8. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, Funder JW & Hu X 2008 A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 51 742-748.
9. Dooley R, Harvey BJ & Thomas W 2012 Non-genomic actions of aldosterone: from receptors and signals to membrane targets. Molecular and Cellular Endocrinology (In press).
10. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER & Monder C 1988 Localisation of 11beta-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 2 986-989.
11. Estébanez-Perpin{ogonek}á E, Moore JM, Mar E, Delgado-Rodrigues E, Nguyen P, Baxter JD, Buehrer BM, Webb P, Fletterick RJ & Guy RK 2005 The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor. Journal of Biological Chemistry 280 8060-8068.
12. Evans RM & Arriza JL 1989 A molecular framework for the actions of glucocorticoid hormones in the nervous system. Neuron 2 1105-1112.
13. Fagart J, Huyet J, Pinon GM, Rochel M, Mayer C & Rafestin-Oblin M-E 2005 Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension. Nature Structural & Molecular Biology 12 554-555.
14. Fagart J, Hillisch A, Huyet J, Bärfacker L, Fay M, Pleiss U, Pook E, Schäfer S, Rafestin-Oblin ME & Kolkhof P 2010 A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. Journal of Biological Chemistry 285 29932-29940.
15. Farman N & Rafestin-Oblin M-E 2001 Multiple aspects of mineralocorticoid selectivity. American Journal of Physiology. Renal Physiology 280 F181-F192.
16. Feldman D, Funder JW & Edelman IS 1973 Evidence for a new class of corticosterone receptor in the rat kidney. Endocrinology 92 1429-1441.
17. Fischer K, Kelly SM, Watt K, Price NC & McEwan IJ 2010 Conformation of the mineralocorticoid receptor N-terminal domain: evidence for induced and stable structure. Molecular Endocrinology 24 1935-1948.
18. Fru KN, VandeVoort CA & Chaffin CL 2006 Mineralocorticoid synthesis during the periovulatory interval in macaques. Biology of Reproduction 75 568-574.
19. Fuller PJ & Verity K 1990 Mineralocorticoid receptor gene expression in the gastro-intestinal tract: distribution and ontogeny. Journal of Steroid Biochemistry 36 263-267.
20. Fuller PJ & Young MJ 2005 Mechanisms of mineralocorticoid action. Hypertension 46 1227-1235.
21. Fuller PJ, Lim-Tio SS & Brennan FE 2000 Specificity in mineralocorticoid versus glucocorticoid action. Kidney International 57 1256-1264.
22. Fuller PJ, Yao Y, Young MJ & Rogerson FM 2010 Identification and characterisation of ligand-specific co-activators of the mineralocorticoid receptor. 92nd Annual Meeting of the Endocrine Society, San Diego, Abstract June 2010.
23. Funder JW, Pearce PT, Smith R & Smith AI 1988 Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242 583-585.
24. Fuse H, Kitagawa H & Kato S 2000 Characterization of transactivational property and coactivator mediation of rat mineralocorticoid receptor activation function-1 (AF-1). Molecular Endocrinology 14 889-899.
25. Geerling JC & Loewy AD 2009 Aldosterone in the brain. American Journal of Physiology. Renal Physiology 297 F559-F576.
26. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke G, Tsai FT, Sigler PB & Lifton RP 2000 Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 289 119-123.
27. Gomez-Sanchez EP, Venkataraman MT, Thwaites D & Fort C 1990 ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. American Journal of Physiology 258 E649-E653.
28. Gronemeyer H, Gustafsson JÅ & Laudet V 2004 Principles for modulation of the nuclear receptor superfamily. Nature Reviews 3 950-964.
29. Grossmann C & Gekle M 2012 Interaction between mineralocorticoid receptor and epidermal growth factor receptor signalling. Molecular and Cellular Endocrinology (In press).
30. He B, Kemppainen JA, Voegel JJ, Gronemeyer H & Wilson EM 1999 Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH2-terminal domain. Journal of Biological Chemistry 274 37219-37225.
31. He B, Kemppainen JA & Wilson EM 2000 FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. Journal of Biological Chemistry 275 22986-22994.
32. Hellal-Levy C, Fagart J, Souque A & Rafestin-Oblin ME 2000 Mechanistic aspects of mineralocorticoid receptor activation. Kidney International 57 1250-1255.
33. Hoppmann J, Perwitz N, Meier B, Fasshauer M, Hadaschik D, Lehnert H & Klein J 2010 The balance between gluco-and mineralo-corticoid action critically determines inflammatory adipocyte responses. Journal of Endocrinology 204 153-164.
34. Hultman ML, Krasnoperova NV, Li S, Du S, Xia C, Dietz JD, Lala DS, Welsch DJ & Hu X 2005 The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms. Molecular Endocrinology 19 1460-1473.
35. In{ogonek}iguez-Lluhi JA & Pearce D 2000 A common motif within the negative regulatory regions of multiple factors inhibits their transcriptional synergy. Molecular and Cellular Biology 20 6040-6050.
36. Jausons-Loffreda N, Chabret C & Pons M 1994 Role of the A/B region of the human mineralocorticoid receptor in aldosterone response selectivity. Biochemical and Biophysical Research Communications 205 1610-1616.
37. Joëls M, Karst H, DeRijk R & de Kloet R 2007 The coming out of the brain mineralocorticoid receptor. Trends in Neurosciences 31 1-7.
38. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A & Redelmeier DA 2004 Rates of hyperkalemia after publication of the randomized aldactone evaluation study. New England Journal of Medicine 351 543-551.
39. Keightley M-C, Curtis AJ, Chu S & Fuller PJ 1998 Structural determinants of cortisol resistance in the guinea pig glucocorticoid receptor. Endocrinology 139 2479-2485.
40. Kino T, Jaffe H, Amin ND, Chakrabarti M, Zheng Y-L, Chrousos GP & Pant HC 2010 Cyclin-dependent kinase 5 modulates the transcriptional activity of the mineralocorticoid receptor and regulates expression of brain-derived neurotrophic factor. Molecular Endocrinology 24 941-952.
41. Kitagawa H, Yanagisawa J, Fuse H, Ogawa S, Yogiashi Y, Okuno A, Nagasawa H, Nakajima T, Matsumoto T & Kato S 2002 Ligand-selective potentiation of rat mineralocorticoid receptor activation function cerase complex. Molecular and Cellular Biology 22 3698-3706.
42. Langley E, Zhou ZX & Wilson EM 1995 Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. Journal of Biological Chemistry 270 29983-29990.
43. Li Y, Suino K, Daugherty J & Xu HE 2005 Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor. Molecular Cell 19 367-380.
44. Lombes M, Kenouch S, Souque A, Farman N & Rafestin-Oblin ME 1994 The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11 beta-hydroxysteroid dehydrogenase. Endocrinology 135 834-840.
45. Luisi BF, Xu WX, Otwinowski Z, Freedman LP, Yamamoto KR & Sigler PB 1991 Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature 352 497-505.
46. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P et al. 1995 The nuclear receptor superfamily: the second decade. Cell 83 835-839.
47. Martinez ED, Pattabiraman N & Danielsen M 2005 Analysis of the hormonebinding domain of steroid receptors using chimeras generated by homologous recombination. Experimental Cell Research 308 320-333.
48. Massaad C, Lombe's M, Aggerbeck M, Rafestin-Oblin M-E & Barouki R 1997 Cell-specific, promoter-dependent mineralocorticoid agonist activity of spironolactone. Molecular Pharmacology 51 285-292.
49. Métivier R, Stark A, Flouriot G, Hübner MR, Brand H, Penot G, Manu D, Denger S, Reid G, Kos M et al. 2002 A dynamic structural model for estrogen receptor-a activation by ligands, emphasizing the role of interactions between distant A and E domains. Molecular Cell 10 1019-1032.
50. Mihailidou AS & Funder JW 2005 Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids 70 347-351.
51. Miner JN, ChangW, Chapman MS, Finn PD, Hong MH, López FJ, Marschke KB, Rosen J, Schrader W, Turner R et al. 2007 An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology 148 363-373.
52. Nordeen SK, Bona BJ, Beck CA, Edwards DP, Borror KC & DeFranco DB 1995 The two faces of a steroid antagonist: when an antagonist isn't. Steroids 60 97-104.
53. Odermatt A & Atanasov AG 2008 Mineralocorticoid receptors: emerging complexity and functional diversity. Steroids 74 163-171.
54. Odermatt A, Arnold P & Frey FJ 2001 The intracellular localization of the mineralocorticoid receptor is regulated by 11beta-hydroxysteroid dehydrogenase type 2. Journal of Biological Chemistry 276 28484-28492.
55. Pascual-Le Tallec L, Simone F, Viengchareun S, Meduri G, Thirman MJ & Lombe's M 2003 Protein inhibitor of activated signal transducer and activator of transcription 1 interacts with the N-terminal domain of mineralocorticoid receptor and represses its transcriptional activity: implication of small ubiquitin-related modifier 1 modification. Molecular Endocrinology 17 2529-2542.
56. Pippal JB, Yao Y, Rogerson FM & Fuller PJ 2009 Structural and functional characterisation of the interdomain interaction in the mineralocorticoid receptor. Molecular Endocrinology 23 1360-1370.
57. Pippal JB, Cheung CMI, Yao Y-Z, Brennan FE & Fuller PJ 2011 Characterization of the zebrafish (Danio rerio) mineralocorticoid receptor. Molecular and Cellular Endocrinology 332 58-66.
58. Pitt B 2004 Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Molecular and Cellular Endocrinology 217 53-58.
59. Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EAG, Goeliner JJ, Funder JW &McMahon EG 2003 Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circulation Research 93 69-76.
60. Quigley CA, Tan JA, He B, Zhou ZX, Mebarki F, Morel Y, Forest MG, Chatelain P, Ritzén EM, French FS et al. 2004 Partial androgen insensitivity with phenotypic variation caused by androgen receptor mutations that disrupt activation function 2 and the NH(2)-and carboxyl-terminal interaction. Mechanisms of Ageing and Development 125 683-695.
61. Rafestin-Oblin ME, Souque A, Bocchi B, Pinon G, Fagart J & Vandewalle A 2003 The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related. Endocrinology 144 528-533.
62. Rickard AJ & Young MJ 2009 Corticosteroid receptors, macrophages and cardiovascular disease. Journal of Molecular Endocrinology 42 449-459.
63. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ & Young MJ 2009 Deletion of mineralocorticoid receptors from macrophages protects against DOC/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54 537-543.
64. Robin-Jagerschmidt C, Wurtz J-M, Guillot B, Gofflo D, Benhamou B, Vergezac A, Ossart C, Moras D & Philibert D 2000 Residues in the ligand binding domain that confer progestin or glucocorticoid specificity and nodulate the receptor transactivation capacity. Molecular Endocrinology 14 1028-1037.
65. Rogerson FM & Fuller PJ 2003 Interdomain interactions in the mineralocorticoid receptor. Molecular and Cellular Endocrinology 200 45-55.
66. Rogerson FM, Dimopoulos N, Sluka P, Chu S, Curtis AJ & Fuller PJ 1999 Structural determinants of aldosterone binding selectivity in the mineralocorticoid receptor. Journal of Biological Chemistry 274 36305-36311.
67. Rogerson FM, Yao YZ, Smith BJ, Dimopoulos N & Fuller PJ 2003 Determinants of spironolactone binding specificity in the mineralocorticoid receptor. Journal of Molecular Endocrinology 31 573-582.
68. Rogerson FM, Yao Y-Z, Smith BJ & Fuller PJ 2004 Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor. Clinical and Experimental Pharmacology & Physiology 31 704-709.
69. Rogerson FM, Yao Y-Z, Elsass RE, Dimopoulos N, Smith BJ & Fuller PJ 2007 A critical region in the mineralocorticoid receptor for aldosteorne binding and activation by cortisol: evidence for a common mechanism governing ligand binding specificity in steroid hormone receptors. Molecular Endocrinology 21 817-828.
70. Rossier MF, Lenglet S, Vetterli L, Python M & Maturana A 2008 Corticosteroids and redox potential modulate spontaneous contractions in isolated rat ventricular cardiomyocytes. Hypertension 52 721-728.
71. Sato A & Funder JW 1996 High glucose stimulates aldosterone-induced hypertrophy via type 1 mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology 137 4145-4153.
72. Savkur RS & Burris TP 2004 The coactivator LXXLL nuclear receptor recognition motif. Journal of Peptide Research 63 207-212.
73. Schaufele F, Carbonell X, Guerbadot M, Borngraeber S, Chapman MS, Ma AA, Miner JN & Diamond MI 2005 The structural basis of androgen receptor activation: intramolecular and intermolecular aminocarboxy interactions. PNAS 102 9802-9807.
74. Sturm A, Bury N, Dengreville L, Fagart J, Flouriot G, Rafestin-Oblin ME & Prunet P 2005 11-Deoxycorticosterone is a potent agonist of the rainbow trout (Oncorhynchus mykiss) mineralocorticoid receptor. Endocrinology 146 47-55.
75. Tetel MJ, Giangrande PH, Leonhardt SA, McDonnell DP & Edwards DP 1999 Hormone-dependent interaction between the amino-and carboxylterminal domains of progesterone receptor in vitro and in vivo. Molecular Endocrinology 13 910-924.
76. Thompson J, Saatcioglu F, Jänne OA & Palvimo JJ 2001 Disrupted aminoand carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity. Molecular Endocrinology 15 923-935.
77. Trapp T & Holsboer F 1995 Ligand-induced conformational changes in the mineralocorticoid receptor analysed by protease mapping. Biochemical and Biophysical Research Communications 215 286-291.
78. Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schütz G, Lumeng CN & Mortensen RM 2010 Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. Journal of Clinical Investigation 120 3350-3364.
79. Viengchareun S, Le Menuet D, Martinerie L, Munier M, Pascual-Le Tallec L & Lombes M 2007 The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nuclear Receptor Signalling 5 e05012.
80. Vivat V, Gofflo D, Wurtz J-M, Bourguet W, Philibert D & Gronemeyer H 1997 Sequences in the ligand-binding domains of the human androgen and progesterone receptors which determine their distinct ligand identities. Journal of Molecular Endocrinology 18 147-160.
81. Wilson P, Morgan J, Funder JW, Fuller PJ & Young MJ 2009 Mediators of mineralocorticoid receptor-induced profibrotic inflammatory responses in the heart. Clinical Science 116 731-739.
82. Yang J & Fuller PJ 2012 Interactions of the mineralocorticoid receptor-within and without. Molecular and Cellular Endocrinology (In press).
83. Yang J & Young MJ 2009 The mineralocorticoid receptor and its coregulators. Journal of Molecular Endocrinology 43 53-64.
84. Yang J, Chang C-Y, Safi R, Morgan J, McDonnell DP, Fuller PJ, Clyne CD & Young MJ 2011 Identification of ligand-selective peptide antagonists of the mineralocorticoid receptor using phage display. Molecular Endocrinology 25 32-43.
85. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ & Pitt B (EMPHASIS-HF Study Group) 2011 Eplerenone in patients with systolic heart failure and mild symptoms. New England Journal of Medicine 364 11-21.
86. Zhang J, Simisky J, Tsai FT & Geller DS 2005 A critical role of helix 3-helix 5 interaction in steroid hormone receptor function. PNAS 102 2707-2712.